Search clinical trials for: RAD001, everolimus

Total 1065 results

University Medical Center Groningen
Novartis Pharmaceuticals

Completed

89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors (NETPET)

Neuroendocrine Tumors

Netherlands
Memorial Sloan Kettering Cancer Center
Novartis

Completed

A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center
Novartis; OSI Pharmaceuticals

Terminated

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
Novartis

Completed

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Breast Cancer | Neoplasm Metastasis

United States
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1)

Breast Cancer

China, United States, France, Italy, United Kingdom, Taiwan, Turkey, Egypt, Germany, Hong Kong, Belgium, Canada, Russian Federation, Lebanon, Japan, Australia, Greece, Korea, Republic of, Ireland, Peru, Argentina, Brazil, Colombia, South... and more
Jonsson Comprehensive Cancer Center

Completed

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Central Nervous System Metastases

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

Tongue Cancer | Recurrent Colon Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral... and other conditions

United States
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
German Breast Group
Novartis

Terminated

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane (Evelyn)

Metastatic Breast Cancer

Germany
University of California, Davis
Novartis

Terminated

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Organisation for Oncology and Translational Research

Unknown

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

China
University of Luebeck

Terminated

Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion (SCORE-CTO)

Coronary Artery Disease

Germany
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Completed

Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Malignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Atypical Teratoid/Rhabdoid Tumor | Refractory Diffuse Intrinsic Pontine Glioma | CNS Embryonal Tumor, Not Otherwise Specified

United States
Roswell Park Cancer Institute
Bayer

Completed

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Unspecified Adult Solid Tumor, Protocol Specific | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (COOPERATE-1)

Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System

Germany
Novartis Pharmaceuticals

Completed

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis (4EVERUK)

Oestrogen Receptor Positive Advanced Breast Cancer

United Kingdom
Fox Chase Cancer Center

Recruiting

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Metastatic Pancreatic Cancer

United States
Novartis Pharmaceuticals

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program (Senator)

Renal Transplantation

Germany
Leiden University Medical Center

Unknown

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Head and Neck Cancer

Netherlands
M.D. Anderson Cancer Center
Novartis

Terminated

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Kidney Cancer

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast Cancer

Israel
Novartis Pharmaceuticals

Completed

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Breast Neoplasm

United States, Germany, Spain, United Kingdom, France, Austria, Russian Federation, Italy, Canada, Belgium
German Breast Group
Novartis

Completed

Dose EScalation Induction of EvERolimus (Desiree)

Breast Cancer | Hormone Receptor Positive Tumor

Germany
Abbott Medical Devices

Completed

A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System (STRIDES)

Atherosclerosis | Peripheral Vascular Disease

Germany, Austria, Belgium, Italy
ARCAGY/ GINECO GROUP

Completed

Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer (ENDORAD)

Endometrial Cancer

France
PrECOG, LLC.
Novartis

Completed

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (PrE0102)

Metastatic Breast Cancer

United States
Mayo Clinic

Completed

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
Fox Chase Cancer Center

Completed

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Novartis Pharmaceuticals

Terminated

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (CATChEz)

Carcinoma, Renal Cell

Australia, Korea, Republic of
Centre Leon Berard

Suspended

A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (CHONRAD)

Chondrosarcoma

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Everolimus in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Dana-Farber Cancer Institute; Novartis Pharmaceuticals

Completed

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Malignant Pleural Mesothelioma

United States
Yonsei University

Completed

A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Epilepsy and Focal Cortical Dysplasia II

Korea, Republic of
Julie E. Bauman, MD, MPH
Novartis

Terminated

Phase II Study of RAD001 Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Yonsei University

Unknown

Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation (ANCHOR)

Coronary Artery Disease

Korea, Republic of
Umberto I Hospital, Frosinone Italy

Unknown

Study of ABSORB Stent in Acute Myocardial Infarction (ABSORB-ACS)

Acute Myocardial Infarction | Artery; Deformity, Coronary (Acquired)

Italy
M.D. Anderson Cancer Center
Susan G. Komen Breast Cancer Foundation

Terminated

Exemestane-RAD001-Metformin

Breast Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Oregon Health and Science University

Completed

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Prostate Cancer | Metastatic, Androgen Independent Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Stage... and other conditions

United States
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Radboud University Medical Center
Novartis

Completed

Influence of Exceptional Patient Characteristics on Everolimus Exposure (INPRES)

Breast Neoplasms

Netherlands
Hopital Foch

Completed

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (AFINIVEST)

Urothelial Cancer

France
Yonsei University

Unknown

A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions

Coronary Artery Disease

Korea, Republic of
University of Chicago
Novartis Pharmaceuticals

Terminated

Everolimus Versus Placebo in Head and Neck Cancer

Head and Neck Cancer

United States
Yonsei University

Completed

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Head and Neck Cancer

Korea, Republic of
Institut National de la Santé Et de la Recherche...

Terminated

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Kaposi Sarcoma

France
Novartis Pharmaceuticals

No longer available

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Advanced Hormone Receptor Positive (HR+) Breast Cancer
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (XIENCE V India)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

India
Abbott Medical Devices

Completed

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (SPIRIT V)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Ireland, Netherlands, Singapore, Spain, China, Belgium, Switzerland, Thailand, Israel, Germany, New Zealand, United Kingdom, Italy, Malaysia, Canada, India, Austria, France, South Africa, Portugal, Czech Republic, Greece, Sweden
Abbott Medical Devices

Completed

ABSORB II Randomized Controlled Trial (ABSORB II)

Coronary Artery Disease

Belgium

Search clinical trials for: RAD001, everolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations